Ftse Mib
32.665,21
-2,81%
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.537,56
0,52%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Transgene S.A. ADS (MM) (TRGNY) Transgene S.A. ADS (MM) (TRGNY) Notizie

TRGNY

Transgene . (TRGNY)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TRGNY
DataOraFonteTitoloSimboloCompagnia
19/10/200508:00PR Newswire (US)Transgene : Cash Position and Net Cash Expenditures as of September 30, 2005NASDAQ:TRGNY
21/09/200507:01PR Newswire (US)Transgene to Voluntarily Delist From NasdaqNASDAQ:TRGNY
03/08/200507:01PR Newswire (US)Transgene Announces First Half 2005 Financial ResultsNASDAQ:TRGNY
21/07/200507:01PR Newswire (US)Transgene Announces Achievement of Clinical Milestone by Merck & Co., Inc. Using Transgene's Proprietary TechnologyNASDAQ:TRGNY
11/07/200519:01PR Newswire (US)Transgene Raises Euro 34.9 MillionNASDAQ:TRGNY
20/05/200507:01PR Newswire (US)Transgene Announces 20-F Form FilingNASDAQ:TRGNY
17/05/200507:01PR Newswire (US)Transgene's Therapeutic Vaccine MVA-MUC1-IL2 at ASCO:NASDAQ:TRGNY
16/05/200507:01PR Newswire (US)Transgene Presents Updated Positive Phase II Data of Its Therapeutic Vaccine MVA-MUC1-IL2 In Prostate Cancer at Annual ASCO MeetNASDAQ:TRGNY
26/04/200507:01PR Newswire (US)Transgene to Present at the 2nd Rodman & Renshaw Annual Global Healthcare ConferenceNASDAQ:TRGNY
13/04/200507:01PR Newswire (US)Transgene: Cash Position and Net Cash Expenditures as of March 31, 2005NASDAQ:TRGNY
05/04/200507:01PR Newswire (US)Transgene to Present Phase II Data of Its MVA-UC1-IL2 Cancer Vaccine at ASCO's 2005 Annual MeetingNASDAQ:TRGNY
23/02/200507:00PR Newswire (US)Transgene Announces Fiscal Year 2004 Financial ResultsNASDAQ:TRGNY
23/02/200507:00PR Newswire (US)Transgene: New Strategy in Therapeutic Vaccines, MVA-Muc1-IL2 Meets Primary Endpoint in Lung Cancer Phase IINASDAQ:TRGNY
15/02/200506:01PR Newswire (US)Transgene Appoints Jean-Yves Bonnefoy as New Chief Scientific OfficerNASDAQ:TRGNY
08/12/200406:01PR Newswire (US)Transgene Appoints Philippe Archinard As New Chief Executive OfficerNASDAQ:TRGNY
30/11/200417:34PR Newswire (US)Transgene Moves Forward Its Vaccine Candidate MVA-HPV-IL2 In A Novel Approach Against Pre-Cancerous Cervical LesionsNASDAQ:TRGNY
03/11/200406:01PR Newswire (US)Transgene: Cash Position and Net Cash Expenditures as of September 30, 2004NASDAQ:TRGNY
04/08/200407:01PR Newswire (US)Transgene Announces Second Quarter and First Half 2004 Financial ResultsNASDAQ:TRGNY
01/07/200415:31PR Newswire (US)Transgene Manufactures Clinical Lots of HIV Vaccine Candidates for the EUROVAC ProjectNASDAQ:TRGNY
15/06/200408:00PR Newswire (US)Merial and Transgene Sign a Collaboration Agreement to Develop Products for Animal HealthNASDAQ:TRGNYTransgene S.A. ADS (MM)
08/06/200407:01PR Newswire (US)Transgene Presents Data on MVA-MUC1-IL2 Cancer Vaccine at ASCO and ASGT Annual MeetingsNASDAQ:TRGNY
12/05/200415:45PR Newswire (US)Transgene to Present Data at 2004 ASCO Annual MeetingNASDAQ:TRGNY
05/05/200407:01PR Newswire (US)Transgene Announces First Quarter 2004 Financial ResultsNASDAQ:TRGNY
14/04/200407:01PR Newswire (US)Transgene: Data Presented at The American Association of Cancer Research Annual Meeting Suggest Significant Opportunities for AnNASDAQ:TRGNY
18/03/200406:01PR Newswire (US)Transgene's MVA-HPV-IL2 Vaccine Shows Activity in Phase II Clinical TrialNASDAQ:TRGNY
11/02/200406:01PR Newswire (US)Transgene Announces Fourth Quarter and Fiscal Year 2003 Financial ResultsNASDAQ:TRGNY
09/02/200406:00PR Newswire (US)Transgene Reports Positive Interim Phase II Data from MVA-Muc1-IL2 Cancer Vaccine ProgramNASDAQ:TRGNY
05/11/200306:01PR Newswire (US)Transgene Announces Third Quarter 2003 Financial ResultsNASDAQ:TRGNY
03/11/200306:01PR Newswire (US)Transgene Signs Pre-Clinical AIDS Vaccine Manufacturing Agreement With ANRS and INSERMNASDAQ:TRGNY
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TRGNY

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
BPE
Bper Banca
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
BAMI
Banco BPM
BIT
RACE
Ferrari NV
BIT
SPM
Saipem
BIT
G
Generali
BIT
NEXI
Nexi S.p.A
BIT
TIT
Telecom Italia
BIT
PST
Poste Italiane S.p.a
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network